Review
5HT3-antagonist receptors: their role in drug-induced emesis
Affiliations
- PMID: 1983228
Item in Clipboard
Review
5HT3-antagonist receptors: their role in drug-induced emesis
Nouv Rev Fr Hematol (1978).
1990.
Abstract
Chemotherapy-induced emesis is the most severe side effect in term of patient's perception. Current anti-emetic regimen as high dose metoclopramide can achieve a complete response in less than 60% of patients. The HT3 receptors appear to be the principal mediator of the emetic effect and their blockade have a clear activity in the prevention of acute drug-induced emesis, superior to reference regimens.
Similar articles
-
Emesis and anti-emesis.Cancer Surv. 1994;21:117-35. Cancer Surv. 1994. PMID: 8564988 Review.
-
Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods.Pharmazie. 2005 Feb;60(2):83-96. Pharmazie. 2005. PMID: 15739895 Review.
-
Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.Semin Oncol. 1994 Oct;21(5 Suppl 9):20-6. Semin Oncol. 1994. PMID: 9113123 Clinical Trial.
-
Preliminary experience with use of a selective 5HT3 receptor antagonist (ondansetron) to prevent high dose chemotherapy induced emesis.Indian J Cancer. 1996 Mar;33(1):17-20. Indian J Cancer. 1996. PMID: 9063013 Clinical Trial.
-
Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.Semin Oncol. 1994 Oct;21(5 Suppl 9):7-11. Semin Oncol. 1994. PMID: 9113120 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical